Biofunctional films and methods of use thereof for the prevention of post-operative adhesions are disclosed.

The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain with a molecular weight of >50 kDa, for the prevention or treatment of adhesions at tissues or organs, in particular peritoneal adhesions following surgical interventions.

Administration of an antibody that, specifically binds IL-1α is useful for reducing the chance or severity of a major adverse clinical event occurring in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel, and for reducing the change of restenosis occurring (or increasing the time until restenosis occurs) in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel.

Provided is a method for purifying α-thrombin and for quantifying α-thrombin and its degradation polypeptides in a liquid proteinatious solution. The method employs a one-step anion exchange chromatography method. The method allows purification and/or quantification of a homogenous post-translationally modified α-thrombin. The method can also be used for purification and/or quantification of β-thrombin.

The present invention concerns a process for the preparation and purification of the sodium salt of HA from the fermentation broth of Streptococcus or Bacillus or from rooster combs, the sodium salt of HA obtained and purified with said process and pharmaceutical, cosmetic and nutritional compositions comprising said sodium salt of HA.

The present invention concerns a process for the preparation and purification of the sodium salt of HA from the fermentation broth of Streptococcus or Bacillus or from rooster combs, the sodium salt of HA obtained and purified with said process and pharmaceutical, cosmetic and nutritional compositions comprising said sodium salt of HA.

Disclosed herein are compositions and methods for use in reducing lung function inhibition.

Disclosed herein are compositions and methods for use in reducing lung function inhibition.

The present invention describes a process for obtaining extracellular matrix from the skin of tilapia (Oreochromis niloticus) comprising the steps of chemical and enzymatic decellularization, detoxification, chemical disinfection, crosslinking, bleaching, dehydration and sterilization by gamma radiation, more specifically the steps comprised by each of said procedures and use of the extracellular matrix for treating ruptured of tissues, dermatitises, acute, chronic and traumatic lesions, battlefield wounds, necrotic wounds, lacerations, abrasions, bruises and other lesions and conditions. The present invention falls within the fields of pharmacy, medicine and veterinary medicine, dentistry, chemistry, tissue engineering, molecular biology and biotechnology.

The present invention is directed to an oligonucleotide comprising a nucleic acid sequence of SEQ ID No. 1 or parts thereof, wherein 1 to 4 nucleotides at the 3′-end and/or at the 5′-end of the oligonucleotide are modified at a base, a sugar and/or a phosphate for use in a method of reducing or inhibiting of scarring, of fibrotic closure of the trabeculectomy canal, of epithelial-to-mesenchymal transition of the trabecular meshwork and/or providing of protecting activity of the optic nerve optionally the optic nerve head. Further, the present invention refers to a pharmaceutical composition comprising such oligonucleotide and a pharmaceutically acceptable carrier.